First Header Logo Second Header Logo

Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.

Rocha-Lima CM, Herndon JE, Lee ME, Atkins JN, Mauer A, Vokes E, Green MR. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol. 2007 Feb; 18(2):331-7.

View in: PubMed